AstraZeneca’s Lynparza to dominate PARP inhibitors market with $4 bn in sales by 2027: GlobalData Read more
DCGI approves AstraZeneca’s Lynparza for adjuvant treatment of patients with high-risk early breast cancer Read more
EU approves AstraZeneca’s Lynparza for patients with germline BRCA-mutated HER2-negative high-risk early breast cancer Read more